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In order to test the ability of peripheral blood gene expression proﬁles to predict future disease severity in patients with early
rheumatoid arthritis (RA), a group of 17 patients (1 ± 0.2 years disease duration) was evaluated at baseline for gene expression
proﬁles. Disease status was evaluated after a mean of 5 years using an index combining pain, global and recoded MHAQ
scores. Unsupervised and supervised algorithms identiﬁed “predictor genes” whose combined expression levels correlated with
follow-up disease severity scores. Unsupervised clustering algorithms separated patients into two branches. The only signiﬁcant
diﬀerencebetweenthesetwogroupswasthediseaseseverityscore;demographicvariablesandmedicationusagewerenotdiﬀerent.
Supervised T-Test analysis identiﬁed 19 “predictor genes” of future disease severity. Results were validated in an independent
cohort of subjects of established RA with using Support Vector Machines and K-Nearest-Neighbor Classiﬁcation. Our study
demonstrates that peripheral blood gene expression proﬁles may be a useful tool to predict future disease severity in patients
with early and established RA.
Copyright © 2009 Zheng Liu et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Rheumatoid arthritis (RA) is a chronic, inﬂammatory joint
disease with autoimmune features. Substantial evidence
suggests that early intervention in individuals with RA
results in improved control of disease activity, decreased
joint damage, and fewer extraarticular manifestations [1–3].
EarlyRApatientsmaybeneﬁtfromearlyaggressivetherapies,
such as new biologic agents that block the activity of
TNF-α(TumorNecrosisFactoralpha),whichcontroldisease
activity and joint destruction [4, 5]. However, these biologic
agents are generally expensive and up to 30% of RA patients
have incomplete responses [6, 7]. These drugs also have
signiﬁcant side eﬀects including increased severe infection
and other autoimmune manifestations. In the approximately
30% of early RA patients who do not develop erosions [7],
treatmentwithTNFblockersmaynotbenecessary,andother
d r u g ss u c ha sm e t h o t r e x a t em a yb es u ﬃcient. These clinical
issues highlight the need for new approaches that would
permit individualization of therapy for patients with early
RAincluding developmentofadditional prognostic markers.
Current prognostic methods for RA are generally based
on the integrated use of information derived from patient
self-assessment questionnaires, the physical examination,
routine laboratory studies such as (erythrocyte sedimenta-
tion rate) ESR and (C-reactive protein) CRP and radio-
graphic ﬁndings. Titer of rheumatoid factor and anti-
CCP (antibodies to cyclic citrullinated peptides), imaging
methods, including conventional X-rays, ultrasound and
magnetic resonance, and genetic markers, such as HLA-
DRB1 alleles, have also been employed [8–12]. Most diag-
nostic methodsaredependentonthediagnostic teststhatare
evaluated. This may result in circularity and overestimation
of the diagnostic properties of the tests [13–15]. Considering
the prevalence of RA, which is estimated as 1% of the
US population (NIAMS, National Institute of Arthritis and2 Human Genomics and Proteomics
Musculoskeletal and Skin Diseases 2004), even a small
increase in the accuracy of disease severity prediction has the
potential to beneﬁt a substantial number of RA patients.
Microarrays provide a powerful tool to screen expression
levels of thousands of genes in single samples. We and
others have used this approach to identify gene expression
signatures in peripheral blood mononuclear cells (PBMCs)
of individuals with autoimmune diseases, including RA,
systemic lupus erythematosus [16], multiple sclerosis, and
type I diabetes mellitus [17–21]. We also have described a
unique gene expression signature that distinguishes patients
with early RA from those with more established disease [22].
The objective of the present study was to determine if gene
expression signatures collected early in the course of RA
could predict future disease severity.
2.MaterialsandMethods
2.1. Patients. The 17 patients with early RA and 9 patients
with established RA used for this study were included in
previous reports [17–21]. We collected blood samples from
17 patients with early RA and 9 patients with established
R Aa n da n a l y z e dd i ﬀerential gene expression proﬁles using
microarrays at an earlier date (2001-2002). At the time of
blood collection, the mean SEM disease duration of early RA
patients was 1 ± 0.2 years and of established RA patients was
10 ± 2 years. Follow-up clinical information was obtained by
one of the investigators (T.S.) as part of ongoing longitudinal
investigations. Clinical evaluations were performed 5.0 ±1.3
years after blood collection and microarray analysis. Self-
assessment evaluations collected at the time of the follow-
up analysis included 100mm visual analog scales for pain
and global assessment and a modiﬁed health assessment
questionnaire (recoded MHAQ). Each of these measures was
converted to an indexed score. “Pain” and “Global”: 0 = 0–9,
1 = 10–29, 2 = 30–59, and 3 = ≥60; “Recoded MHAQ”: 0 =
0, 1 = 0.13–0.25, 2 = 0.38–0.50, 3 = 0.63–1.0, and 4 = >1.0.
An overall composite index score was then calculated as a
sumof the three-scorecomponents. The overalldisease score
had a possible range of 0–10, with scores of 0–3 considered
mild and scores of 4–10 classiﬁed as severe. Determination
of clinical course was blinded to results of the microarray
analysis.
Vanderbilt University Institutional Review Board ap-
provedthisstudy.Allparticipantsprovidedwritteninformed
consent.
2.2. Sample Preparation and Microarray Procedures. PBMC
were isolated from 20mL heparinized blood on a Ficoll-
Hypaque gradient. All samples were processed within 2–4
hours of blood collection. Total RNA was isolated with Tri-
Reagent (Molecular Research Center. Inc., Cincinnati OH)
and 5μg RNA was used to prepare cDNA with reverse tran-
scriptase (Superscript II, Invitrogen Corporation, Carlsbad,
CA) in the presence of 33P-dCTP. Labeled probes were
puriﬁed using a Bio-Spin 6 Chromatography Column (Bio-
Rad Laboratories, Inc., Hercules, CA). Before hybridiza-
tion, GeneFilters membranes (GF-211, Research Genet-
ics/Invitrogen Corporation, Carlsbad, CA) were washed in
boiled 0.5% SDS, saturated with 5.0mL Microhyb solution
(HYB125.GF, Research Genetics/Invitrogen Corporation,
Carlsbad, CA). Filters were treated with prehybridization
reagents (5.0μg Human Cot-1 DNA and 5.0μgP o l yd A ,
Invitrogen Corporation, Carlsbad, CA) in a hybridization
roller tube (Midwest Scientiﬁc, St. Louis MO) for 2 hours
at 42◦C. Puriﬁed, labeled probes were denatured and added
to roller bottles containing ﬁlters and prehybridization
solution. GeneFilters membranes were hybridized overnight
at 42◦C. After hybridization, membranes were washed
three times, exposed to imaging screens for 24 hours and
screens were scanned by a phosphorimager (Molecular
Dynamics/Amersham Biosciences, Piscataway NJ). Acquired
images were loaded into Pathways 4.0 software (Research
Genetics/Invitrogen Corporation, Carlsbad, CA). The rel-
ative intensity of each spot on the membrane was deter-
mined and the microarray dataset was subjected to further
analysis using the diﬀerent analytical platforms. Data were
normalized to yield an average intensity of 1.0 for each
clone (4133) represented on the microarray. Reproducibility
of the method was established by performing replicate
hybridizations to separate microarrays. Original microarray
data are deposited in the GEO database, accession number
GSE1964 (GSM35124-GSM35142).
2.3. Data Analysis. Cluster (version 3.0) and TIGR microar-
ray software MultiExperiment Viewer (MEV) were used to
identify genes whose expression levels diﬀered signiﬁcantly
among the sample groups. The following data analysis
modules of MEV were used to perform further analyses:
HCL (hierarchical clustering), ST (support tree clustering),
supervised T-Test, SVM (support vector machines), KNNC
(K-Nearest-Neighbor Classiﬁcation), and (principal compo-
nents analysis) PCA. Detailed descriptions of the applica-
tions of these programs to the analysis are provided in the
results section. Analysis procedures presented here comply
with (minimal information about a microarray experiment)
MIAME guidelines established by the Microarray Gene
Expression Data Society (http://www.mged.org). Clinical
variables are shown as mean ± SEM. Statistical analyses
of the clinical data were carried out using Fisher’s exact
test or Student’s T-Test with a P value of <.05 considered
signiﬁcant.
3. Results
3.1. Clustering Analysis of ERA Patient Gene Expression
Proﬁles. We performed unsupervised hierarchical clustering
of gene expression proﬁles of ERA patients. First, the 4133
genes for which we had expression data were ﬁltered at
a standard deviation of 2 using Cluster software. A total
of 192 genes passed this ﬁltering condition. Unsupervised
hierarchical clustering using this 192-gene expression proﬁle
segregated patient samples into two major groups (Figure 1).
We compared patient clinical features to determine if the
patients that segregated into the two clusters exhibited any
common characteristic (Table 1). Age of disease onset, race,
gender, and presence or absence of rheumatoid factor wereHuman Genomics and Proteomics 3
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Figure 1: Unsupervised hierarchical clustering was applied to the expression proﬁle of 192 genes using the ﬁltering condition (SD = 2).
Patients segregated into two clusters: 1 and 2. Diﬀerence of distribution of severe or mild patients in the two clusters was signiﬁcant, P =
.015, Fisher’s Exact Test.
not statistically diﬀerent between individuals in the two
groups. Medication uses of steroids and DMARDs or their
combinations at the time of sample collection were also not
statistically diﬀerent. The only signiﬁcant diﬀerence was the
disease index distribution. In Cluster 1, 8 of the 10 patients
(80%) developed mild disease (green bar) according to the
clinical evaluation 5 ± 1.3 years after patient samples were
collected,whileinCluster2,only1of7(17%)haddeveloped
mild disease (P = .015). The others in Cluster 2 (6 of 7)
were classiﬁed as having severe disease (red bar) at follow-
up. Classiﬁcation of disease severity was performed without
knowledge of the results of the hierarchical clustering
patterns identiﬁed by analysis of gene expression proﬁles.
These results suggest that gene expression proﬁles can be
used to predict future disease severity.
3.2. Supervised T-Test Identiﬁes Predictor Genes. Next, we
employed a supervised method of analysis to identify genes
within the 4133-gene microarray database whose expression
proﬁles predicted future disease severity to permit us to
set certain criteria prior to the gene identiﬁcation process.
The supervised T-Test method was used to identify genes
that were diﬀerentially expressed according to their disease
severity (Figure 2). For this analysis, we divided patients
into the severe disease group and the mild disease group
accordingtotheirclinicalevaluation(seeSection 2.1)andset
the following criteria for the genes: diﬀerence in expression
of identiﬁed genes between the two groups had a P value
<.001 with the multiple test correction applied (adjusted
Bonferroni correction). Statistic t was calculated based
upon 500 permutations for each gene across the 17-patient
samples. Under these stringent conditions, 19 genes were
identiﬁed.
We performed support tree clustering using expression
data of these 19 genes with Jackknife algorithm resampling
with 500 permutations. Support tree clustering not only
Table 1:Clinicalphenotypescorrespondingtoclusterdesignations.
Phenotype Cluster 1 2 P value(a)
Age of onset 61 65 ns
Severity Mild 8 1 .015
Severe 2 6
Race Black 0 2 ns
White 10 5
Gender Female 9 6 ns
Male 1 1
Rf Positive 7 4 ns
Negative 3 3
Disease-modifying antirheumatic drugs (DMARDs)
Prednisone (pred) 5/10 5/7 ns
Methotrexate (mtx) 9/10 6/7 ns
Hydroxychloroquine (hcq) 1/10 2/7 ns
Leﬂunimide [23] 1/10 0/7 ns
Enbrel [24] 1/10 1/7 ns
Remicade [25] 0/10 1/7 ns
All DMARDs 9/10 6/7 ns
(a)Diﬀerence in “age of onset” was calculated by students’ T-test, diﬀerences
inotherphenotypeswerecalculatedbyFisher’sexacttest.ns:notsigniﬁcant.
identiﬁes hierarchical trees but also calculates and shows
the statistical reliability or support for the cluster of the
trees, based upon the Jackknife resampling of the data.
Jackknife resampling takes each gene expression proﬁle
across all the patients and randomly omits a patient. This
method produces an expression proﬁle that has all patients
minus one, which minimizes the eﬀects of single outlier
values. For each resampling process, a hierarchical cluster is
determined and compared to the original clustering result.4 Human Genomics and Proteomics
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Figure 2:Supporttreehierarchicalclusteringwasappliedtotheexpressionproﬁlesof19-predictorgenesamongthe17patients.A.Jackknife
resampling was used with permutation 500 times. The color codes correspond to a given level of support. Branchs 1 and 2 are signiﬁcantly
separated according to their disease severity (P = .00004, Fisher’s Exact Test).
The percentage of the original clustering results that occur
during the number of resamplings indicates the level of
reliability or support for the clustering result. Two major
branches were produced from this analysis (Figure 2). All
patients with future mild disease severity were in one branch
and all patients with future severe disease severity were in
the other branch. Therefore, the support tree results from
Jackknife resampling indicate that there was no obvious
inﬂuence of outliers on gene identiﬁcation and the clustering
proﬁle.
3.3. The 19-Predictor Genes. The 19-predictor genes could
be divided into two groups depending upon whether they
exhibited higher or lower expression in the future mild
and future severe disease groups, respectively (Figure 3).
Normalized polished expression data of these 19 genes in the
severe and mild groups (Figure 3(a)) and original expression
data without normalization (Figure 3(b)) reveals similar
expression patterns in the future severe and mild groups.
Among the 19-predictor genes: FVT1 (follicular lymphoma
variant translocation 1), EHD1 (EH-domain containing 1),
COL4A1 (collagen, type IV, alpha 1), PRMT2 (protein
arginine methyltransferase 2), and TFCP2 (transcription
factor CP2) were underexpressed in the severe patient group
compared to the mild patient group, the other genes: FHL3
(four and a half LIM domains 3), SKIL (SKI-like oncogene),
RPIA (ribose 5-phosphate isomerase A (ribose 5-phosphate
epimerase)), SPRY2 (sprouty homolog 2 (Drosophila)),
F2RL1 (coagulation factor II (thrombin) receptor-like 1),
PPP1R12B (protein phosphatase 1, regulatory (inhibitor)
subunit 12B), LTBR (lymphotoxin beta receptor (TNFR
superfamily, member 3)), GADD45A (growth arrest and
DNA-damage-inducible, alpha), ARHGEF16 (Rho guanine
exchange factor (GEF) 16), MLL (myeloid/lymphoid or
mixed-lineage leukemia (trithorax homolog, Drosophila)),
ACYP1 (acylphosphatase 1, erythrocyte (common) type)),
EIF3S9 (eukaryotic translation initiation factor 3, sub-
unit 9 eta, 116kDa), CACNB2 (calcium channel, voltage-
dependent, beta 2 subunit), and ABCC3 (ATP-binding
cassette, subfamily C (CFTR/MRP), member 3) were over-
expressed in the future severe patient group compared to the
future mild patient group.
3.4. Independent Validation of Disease Severity Signature. To
further explore properties of this 19-gene expression proﬁle,
we applied microarray proﬁling and clinical follow-up to
an independent cohort of patients with established RA (N
= 9, average disease duration of 10 years at the time of
expression proﬁling, 15 years at the time of clinical follow-
up).Expression proﬁling of these RApatients wasperformed
within the same time frame as the ERA patients. After
normalization, expression data for the 19 genes identiﬁed
above were extracted and analyzed using the hierarchical
clustering algorithm (Figure 4(a)). This segregated the 9
RA patient samples into two clusters with 100% support
and these two clusters exactly corresponded to their future
clinical evaluation; group 1: severe disease, group 2: mild
disease. Average expression values of these 19 genes were
also determined for both the severe and mild groups. The
expression diﬀerences for these 19 genes were identical to the
expressionpatternobservedinERApatientswhensegregated
based upon disease severity (Figure 4(b)). FVT1, EHD1,
COL4A1,a n dTPCP2 exhibited lower expression levels in the
severe group of patients than in the mild group of patients.
Conversely, FHL3, SKIL, RPIA, SPRY2, F2RL1, PPP1R12B,
LTBR, GAD45A, ARHGEF1, MLL, ACYP1, EIF3S9, CACNB2,Human Genomics and Proteomics 5
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Figure 3: Identity and expression levels of the 19 genes in individuals comprising the future mild and future severe disease groups are shown
by bar graphs. (a) The normalized polished expression data of these 19 genes in severe and mild groups. (b) The original expression data
without normalization in the future severe and mild groups for the 19-predictor genes. Note that standard deviations are not shown because
the t statistic was calculated based on permutations. Black bars represent the severe group, white bars represent the mild group.
and ABCC3 exhibited higher expression levels in the severe
group of patients compared to the mild group of patients.
ThismirrorswhatwasfoundintheERAgroup(Figure 3(b)).
We employed PCA to examine the ability of the 19-gene
expression proﬁle to discriminate between the combined
RA cohorts, ERA and established RA, based upon future
disease severity. PCA projected the patients into a two-
dimensional plane according to their 19-gene expression
proﬁle (Figure 5). In the two-dimensional plane (X,Y),
patients segregated into two areas that are separated by
the dashed line. The distribution of the patients in 2D
space determined by their 19-gene expression proﬁle by
PCA analysis indicates that the 19-gene predictor system can
segregatethetwoindependentRApatientgroupssolelyupon
their future disease severity rather than other parameters
such as disease duration.
We employed SVM and KNNC methods to determine
if disease severity in the established RA patients could be
predicted based upon expression proﬁles of the 19-gene
expression set identiﬁed from analysis of the ERA patient
set. ERA patients were used as the training set and each ERA
patient was assigned to the severe or mild group according
to both their corresponding 19-gene expression signature
and their clinical evaluation. After SVM training, the SVM
algorithmwasappliedtoclassifythe9RApatientsusingtheir
19-gene expression value. The 9 RA patients were accurately
segregated into the two groups according to their clinical
evaluation with one exception, RA no. 1. RA no. 1 should be
in the severe group according to clinical evaluation, but SVM
classiﬁed it as mild status according to the gene expression
proﬁle (Table 2). Similarly, KNNC was applied to classify
the independent 9 RA patients. They were separated into
two groups by KNNC exactly according to their clinical
evaluation (Table 3). Therefore, with this independent data
set, we conﬁrmed that expression proﬁles of these 19 genes
represent a disease severity signature in RA.
4. Discussion
Disease-modifying therapy early in the course of RA can
leadtoimproveddiseasecontrolanddecreasedjointdamage.
However, the uncertain course of RA in some patients
coupled with the adverse eﬀects and high cost of newer6 Human Genomics and Proteomics
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Figure 4: Hierarchical classiﬁcation of an independent established RA cohort using the 19-gene expression proﬁle. (a) Support tree
hierarchical clustering was applied to the expression proﬁle of the 19-predictor genes in 9 RA patients. Jackknife resampling was used
with 500 permutations. The color codes correspond to a given level of support. Branch 1 and 2 are signiﬁcantly separated according to
their disease severity. (P = .008, Fisher’s Exact Test). (b) The original expression data without normalization in the severe and mild groups
for the 19-predictor genes in 9 RA patients. Note that standard deviations are not shown because the t statistic was calculated based upon
permutations. Black bars represent the severe group and white bars represent the mild group.
therapies make decisions regarding treatment strategies
complex. About 30% of early RA patients will not develop
severe disease and a small number may even undergo remis-
sion without treatment. The current prognostic factors are
relatively powerful tools, including measurement of health
assessmentquestionnaire (HAQ)scores,autoantibody levels,
and genetic markers. Although the prognostic sensitivity of
the combined tests is in range of 80%–90%, this may not be
suﬃcient to predict outcome in an individual patient [7, 25–
27]. Gene expression proﬁling strategies have been widely
used in cancer studies for purposes of diseases classiﬁcation,
evaluation of responses to therapies, and prediction of
disease outcome [23, 24, 26, 28–39]. Similar gene expression
proﬁling strategies have been employed in autoimmune
disease, including RA, to address similar questions [17, 19–
22, 28, 29]. For example, a set of indicator genes has been
identiﬁed that predict responses to the TNF-α blocking
agent, inﬂiximab, in RA [30]. Supervised algorithms were
applied to identify responder genes, whose expression levels
discriminate between those subjects who would respondHuman Genomics and Proteomics 7
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Figure 5: PCA classiﬁcation of ERA and established RA patients by
the 19-gene predictor. Two-dimensional projection of 26 patients
based upon their gene expression levels of 19-predictor genes onto
the (X,Y) plane. Green squares represent the future mild disease
group and red squares represent the future severe disease group.
The dashed line segregates the future severe and mild groups of RA
patients with 100% accuracy.
to inﬂiximab therapy and those subjects who were poorly
responsive to inﬂiximab therapy. Several genes have also
beenidentiﬁedwhoseexpressionlevelscorrelatewithcurrent
disease activity based upon standard measurements of
disease activity including the HAQ score, CRP levels, ESR,
and rheumatoid factor [31]l e v e l s[ 29]. A general view is that
geneexpression levels may provide a more quantitative index
of disease activity than currently available. Although studies
such as these must be validated in larger patient cohorts,
these results suggest it may be possible to employ diﬀerences
in gene expression to estimate disease activity.
Here,wewantedtodetermineifgeneexpressionproﬁling
is a method also able to predict future disease severity in
RA. To explore this question, we compared the clinical status
of subjects with RA to expression data obtained from these
subjects early in their disease. We applied the supervised T-
Test algorithm to identify a combination of 19 genes whose
past expression levels predicted their future clinical course
in a group of 17 patients with early RA. We achieved 100%
(17/17)accuracyofpredictionoffuturediseaseseverityifour
clinical follow-up assessment is 100% accurate.
An independent dataset is optimal to further validate
19-gene prediction system. In this regard, we tested the 19-
gene predictor system using an independent RA data set.
We applied two supervised methods: SVM and KNNC to
validateourresults.SVM[32,33,40–42]andKNNC[28,34–
37] are supervised machine learning algorithms used in gene
expression proﬁling studies. SVM uses kernel function to
build classiﬁcation rules and KNNC uses weighted voting
Table 2: SVM analysis accurately predicts future disease severity in
RA patients using ERA 19-gene expression proﬁles as the training
set.
Training set input
Patient sample SVM input 19-gene class Clinical class
ERA1 Severe Severe Severe
ERA2 Mild Mild Mild
ERA3 Mild Mild Mild
ERA4 Mild Mild Mild
ERA6 Severe Severe Severe
ERA8 Mild Mild Mild
ERA9 Mild Mild Mild
ERA12 Severe Severe Severe
ERA13 Severe Severe Severe
ERA14 Severe Severe Severe
ERA15 Mild Mild Mild
ERA16 Mild Mild Mild
ERA20 Mild Mild Mild
ERA21 Severe Severe Severe
ERA22 Severe Severe Severe
ERA24 Mild Mild Mild
ERA25 Severe Severe Severe
Classiﬁed set output
Patient sample SVM input SVM output Clinical class
RA1 Unassigned Mild Severe
RA2 Unassigned Severe Severe
RA3 Unassigned Mild Mild
RA4 Unassigned Severe Severe
RA5 Unassigned Severe Severe
RA6 Unassigned Severe Severe
RA7 Unassigned Mild Mild
RA8 Unassigned Mild Mild
RA9 Unassigned Mild Mild
Details of the analysis are described in the text.
to designate the class of test samples. There is no general
consensus for which method is superior. Therefore, we
applied both methods to our analysis and both methods
produced almost 100% accuracy for prediction of future
disease severity in RA patients. Our results from SVM and
KNNC are consistent with our clustering analysis and PCA
grouping. Thus, by using an independent cohort of patients
with established RA, we were able to further conﬁrm that
theexpressionproﬁleofthese19-predictorgenesrepresentsa
signature of disease severity in RA. These results also support
thenotionthattheexpressionpatternofthese19genesissta-
ble as a function of disease duration. The expression pattern
exists in both early and established RA patients. Therefore,
this test may have application at any point during the disease
history of an individual with RA. In the independent vali-
dation, only one RA subject, RA no. 1, was not consistently
classiﬁed according to the disease severity status. However,
this patient may develop severe disease later and bears close
monitoring.8 Human Genomics and Proteomics
Table 3: KNNC analysis accurately predicts future disease severity
inRApatientsusingERA19-geneexpressionproﬁlesasthetraining
set.
Training set input
Patient sample KNNC input 19-gene class Clinical class
ERA1 Severe Severe Severe
ERA2 Mild Mild Mild
ERA3 Mild Mild Mild
ERA4 Mild Mild Mild
ERA6 Severe Severe Severe
ERA8 Mild Mild Mild
ERA9 Mild Mild Mild
ERA12 Severe Severe Severe
ERA13 Severe Severe Severe
ERA14 Severe Severe Severe
ERA15 Mild Mild Mild
ERA16 Mild Mild Mild
ERA20 Mild Mild Mild
ERA21 Severe Severe Severe
ERA22 Severe Severe Severe
ERA24 Mild Mild Mild
ERA25 Severe Severe Severe
Classiﬁed set output
Patient sample KNNC input KNNC output Clinical class
RA1 Unassigned Severe Severe
RA2 Unassigned Severe Severe
RA3 Unassigned Mild Mild
RA4 Unassigned Severe Severe
RA5 Unassigned Severe Severe
RA6 Unassigned Severe Severe
RA7 Unassigned Mild Mild
RA8 Unassigned Mild Mild
RA9 Unassigned Mild Mild
Details of analyses are provided in Section 3.
Of the 19 genes comprising our predictor system, ﬁve
are underexpressed in patients who develop a severe disease
phenotype and fourteen genes are overexpressed. At present,
we cannot conclude if expression levels of these genes are
causal factors contributing to the diﬀerential disease severity
orareindicatorsoffuturediseaseactivitysincethemechanis-
tic basis of future disease activity is not well understood. It is
tempting to speculate that better understanding the impact
of alterations in expression levels of this group of genes
may not only improve our ability to predict future disease
activity in RA but may also contribute to our understanding
of mechanisms leading to more severe disease. For example,
SKIL(SKI-likeoncogene),overexpressedintheseveredisease
group, is induced by TGF-β1, whose expression level is pos-
itively correlated with serum levels of CRP, a clinical marker
of disease activity and severity [38]. Further, increased
expression of F2RL1I (also named PAR2, protease-activated
receptor 2) in a murine model of arthritis correlates with
joint swelling and erosion. Inhibition of increased expression
of PAR2 substantially reduces inﬂammatory responses in the
joint [39]. Expression levels of PAR2 are also substantially
increased in RA synovium compared to control synovial
tissue. Spontaneous release of inﬂammatory cytokines is
substantially inhibited by a PAR2 antagonist in a dose-
dependent manner [39]. These results suggest that increased
expression of F2RL1 (PAR2) may contribute to increased
disease activity in RA patients. Although the mechanistic
signiﬁcance of how diﬀerences in expression levels of these
19-predictor genes may inﬂuence future disease severity in
RA is not entirely clear, our results clearly demonstrate that
these diﬀerences in expression may have utility in predicting
future disease outcome.
At the time of sampling, between sampling and clinical
follow-up, and at the time of clinical follow-up, all patients
in our study were on some type of antirheumatic therapy.
Clinically, RA is a very heterogeneous disease and our
system may be able to discriminate between individuals
who will develop aggressive or mild disease. An alternative
interpretation is that expression levels of these 19 genes
actually discriminates between individuals who exhibit good
responses to antirheumatic therapies and therefore develop
mild disease and those patients who exhibit poor responses
to antirheumatic therapies and therefore develop a severe
disease course. Further studies are needed to determine if
expression levels of these 19-predictor genes actually forecast
poor responsiveness to therapy rather than aggressive versus
mild disease.
In this analysis, we considered association of the RA
covariates,diseaseseverity,race,gender,Rftiter,andmedica-
tion usage and found strong association of the 19-predictor
gene signature with disease severity. Although all subjects
were on medications, they did not receive any speciﬁc
treatment at the exact time of their blood draw. Other RA
covariates,suchastheHLA-DRB1sharedepitope[10],ageof
diseaseonset,anti-CCPtiter,educationstatus,tobaccousage,
were not considered in our analysis. These are important
covariates to be considered in future studies.
One advantageof our 19-gene predictor systemis that we
used PBMC as a resource for gene expression proﬁling even
thoughPBMCarenotlocalizedtothesitedirectlyaﬀectedby
the disease of RA. PBMC are a very easily accessible human
tissue sample compared to a surgical biopsy of an aﬀected
tissue. Therefore, PBMC may be a good common resource
for disease related “biomarkers” identiﬁcation. PBMC have
been widely used as a resource for gene expression proﬁling
in RA [17, 21, 22, 28, 30]. PBMC also may represent
a suitable common source for gene expression proﬁling
experiments in other diseases such as certain cancers or
chronicnoninﬂammatorydiseaseswhosemajoraﬀectedsites
are not blood.
In our analysis, we identiﬁed and selected expression
levels of 19 genes as predictors of future disease severity.
Otherinvestigationsusinggeneexpressionproﬁlingmethods
for disease prediction or classiﬁcation have used more genes
in their classifying system [20, 28, 37]. Expression levels of
a greater numbers of genes in a classiﬁcation system have
the potential to produce more accurate results. However,
our 19-gene predictor system achieves 100% accuracy in anHuman Genomics and Proteomics 9
independent test dataset. This indicates that our 19-gene
system is reliable. Further, fewer genes in a classiﬁcation
system can facilitate future clinical implementation and
save potential costs for manufacturing such a test and ease
economical burdens. In summary, our 19-gene predictor
system accurately discriminates between subjects with RA
who will develop severe disease and those who will develop
mild disease with 100% accuracy. These results suggest that
it is possible to predict future disease severity using this type
of approach. We propose that addition of this analysis to
other measures, such as HAQ score, HLA genotyping, and
rheumatoid factor may be useful to predict future disease
severity in early RA patients. This information may be useful
for designing tailor-made therapies for RA patients.
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